Serologicals Corporation Announces Completion of Acquisition of Cytomyx Ltd
News Apr 07, 2006
Serologicals Corporation has announced completed its previously announced acquisition of Cytomyx Ltd., a wholly owned subsidiary of Cytomyx Holdings Plc.
Based in Cambridge, U.K., Cytomyx Ltd. is a provider of ion channel cell lines and drug discovery services. With 23 distinct ion channel cell lines commercially
available, and more in its pipeline, Cytomyx Ltd. offers a large portfolio of distinct ion channel cell lines.
Serologicals paid U.S. $7 million for the stock of Cytomyx Ltd.
“We are very pleased to announce the completion of the Cytomyx Ltd. acquisition,” said David A. Dodd, President and CEO of Serologicals. “Ion channels represent the third largest target class for Biopharma research and drug development today. The expertise that Cytomyx Ltd. brings will greatly enhance our drug discovery products and services portfolio with therapeutically relevant ion channel cell lines and ion channel screening services. With GPCRs, kinases, and ion channels, Serologicals will better serve the needs of our Biopharma customers through a comprehensive portfolio offering.”
Researchers have found that two structurally similar compounds – deguelin and rotenone, naturally occurring pesticides produced by many plant species – interfered with melanoma cancer cells’ metabolism. Further testing with deguelin showed that it inhibited oxygen consumption in the cells’ mitochondria, effectively starving the cells of energy.READ MORE
Researchers report that an experimental drug called vosoritide, allowed the average annual growth rate to increase in a study of 35 children and teenagers with a form of dwarfism. The average boost in height per year was ~6 centimeters (2.4 inches) which is close to growth rates among children of average stature.READ MORE